Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II rollover booster trial of Comirnaty or BNT162b2s01
2021-002387-50Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by BioNTech SE. Primary endpoints: Safety and tolerability of booster doses and Immunogenicity – neutralizing antibody titers. Started Jun 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002387-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002387-50.